Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Karin Rosen (South San Francisco, United States of America), Nicola A. Hanania, Benjamin Trzaskoma, Karin Rosén, Volkan Manga, Theodore A. Omachi. Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status. Eur Respir J 2015; 46: Suppl. 59, 2952

Member's Comments

No comment yet.

Related content which might interest you: Patients with allergic and eosinophilic asthma in the German severe asthma registry Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Asthma control with omalizumab treatment in severe allergic asthma and severe non-allergic asthma patients Source: International Congress 2015 – Asthma and lung immunology Year: 2015 Combined therapy of asthma and allergic rhinitis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Sputum eosinophilia in severe allergic asthma is not a reliable marker of omalizumab treatment Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 The ’real-life’ long-term efficacy of omalizumab in severe persistent IgE-mediated allergic asthma in Malta Source: International Congress 2016 – Asthma management Year: 2016 Clinical effectiveness of anti-IgE therapy in allergic severe asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 APEXII- A prospective study investigating the efficacy of omalizumab treatment in severe allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Predictors factors for asthma in patients with rhinitis Source: International Congress 2014 – Clinical allergy Year: 2014 First clinical trial of a new IgE-adsorber in allergic asthma Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015 Subcutaneous allergen specific immunotherapy and immunological response in patients with bronchial asthma and allergic rhinitis in India Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Risk factors of incomplete asthma control in asthmatic patients with allergic rhinitis Source: Annual Congress 2013 –Asthma Year: 2013 Predictors of exacerbations in asthma Source: International Congress 2015 – Clinical assessment in asthma and COPD Year: 2015 Pharmacogenetics in severity of bronchial hyperresponsiveness in asthma Source: Annual Congress 2013 –Genetic factors in airway development and disease Year: 2013 The impact of psychological distress on allergic rhinitis and asthma control Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Effectiveness of omalizumab in Greek patients with severe allergic asthma (SAA): The SMILE study Source: International Congress 2016 – Asthma points to ponder Year: 2016 Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab Source: International Congress 2014 – More paediatric asthma Year: 2014 Allergic rhinitis does it have an impact on controller asthma therapy choice Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014 Biomarkers of obesity associated with severe atopic asthma Source: International Congress 2015 – Asthma mechanisms and management Year: 2015 Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Long-term using of omalizumab in children with atopic severe persistent non-controlled asthma Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013